2025-2031 Global PD-1 and PD-L1 Monoclonal Antibody Industry Research & Trends Analysis Report- YH Research

Home > Reports >Pharma & Healthcare > 2025-2031 Global PD-1 and PD-L1 Monoclonal Antibody Industry Research & Trends Analysis Report

2025-2031 Global PD-1 and PD-L1 Monoclonal Antibody Industry Research & Trends Analysis Report

Publication Date: 2025-12-12
Report Id: 2862885
Industry: Pharma & Healthcare
Report Page: 132
Chart: 138

PDF Download

Publication Date: 2025-12-12
Report Id: 2862885
Industry: Pharma & Healthcare
Report Page: 132
Chart: 138

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 PD-1 and PD-L1 Monoclonal Antibody Definition
1.2 Global PD-1 and PD-L1 Monoclonal Antibody Market Size and Forecast
1.2.1 By Revenue, Global PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
1.2.2 By Sales Volume, Global PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
1.2.3 Global PD-1 and PD-L1 Monoclonal Antibody Price Trend, 2020-2031
1.3 China PD-1 and PD-L1 Monoclonal Antibody Market Size and Forecast
1.3.1 By Revenue, China PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
1.3.2 By Sales Volume, China PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
1.3.3 China PD-1 and PD-L1 Monoclonal Antibody Price Trend, 2020-2031
1.4 China Percentage in Global Market
1.4.1 By Revenue, China PD-1 and PD-L1 Monoclonal Antibody Share in Global Market, 2020-2031
1.4.2 By Sales Volume, China PD-1 and PD-L1 Monoclonal Antibody Share in Global Market, 2020-2031
1.4.3 PD-1 and PD-L1 Monoclonal Antibody Market Size: China VS Global, 2020-2031
1.5 PD-1 and PD-L1 Monoclonal Antibody Market Dynamics
1.5.1 PD-1 and PD-L1 Monoclonal Antibody Market Drivers
1.5.2 PD-1 and PD-L1 Monoclonal Antibody Market Restraints
1.5.3 PD-1 and PD-L1 Monoclonal Antibody Industry Trends
1.5.4 PD-1 and PD-L1 Monoclonal Antibody Industry Policy

2 Global Competitive Landscape by Company
2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Company, 2020-2025
2.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume by Company, 2020-2025
2.3 Global PD-1 and PD-L1 Monoclonal Antibody Price by Company, 2020-2025
2.4 Global PD-1 and PD-L1 Monoclonal Antibody Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global PD-1 and PD-L1 Monoclonal Antibody Concentration Ratio
2.6 Global PD-1 and PD-L1 Monoclonal Antibody Mergers & Acquisitions, Expansion Plans
2.7 Global PD-1 and PD-L1 Monoclonal Antibody Manufacturers Product Type

3 China Competitive Landscape by Company
3.1 China PD-1 and PD-L1 Monoclonal Antibody Revenue by Company, 2020-2025
3.2 China PD-1 and PD-L1 Monoclonal Antibody Sales Volume by Company, 2020-2025
3.3 China PD-1 and PD-L1 Monoclonal Antibody PD-1 and PD-L1 Monoclonal Antibody Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.4 China PD-1 and PD-L1 Monoclonal Antibody Market, Sales Percentage of Local Players VS Foreign Players (2020-2025)
3.5 Chinese Local Players, PD-1 and PD-L1 Monoclonal Antibody Domestic VS Export
3.6 China Market, PD-1 and PD-L1 Monoclonal Antibody Import & Export
3.6.1 China Market, PD-1 and PD-L1 Monoclonal Antibody Import & Export, 2020-2031
3.6.2 China PD-1 and PD-L1 Monoclonal Antibody Import & Export Trends
3.6.3 Main Sources of China PD-1 and PD-L1 Monoclonal Antibody Import
3.6.4 Export Destination of China PD-1 and PD-L1 Monoclonal Antibody

4 PD-1 and PD-L1 Monoclonal Antibody Production by Region
4.1 Global PD-1 and PD-L1 Monoclonal Antibody Capacity, Production and Capacity Utilization, 2020-2031
4.2 Global Geographic Distribution of PD-1 and PD-L1 Monoclonal Antibody Manufacturers
4.3 Global Major Manufacturers, PD-1 and PD-L1 Monoclonal Antibody Capacity Expansion and Future Plans
4.4 Global PD-1 and PD-L1 Monoclonal Antibody Capacity by Region
4.5 Global PD-1 and PD-L1 Monoclonal Antibody Production by Region
4.5.1 Global PD-1 and PD-L1 Monoclonal Antibody Production & Forecast by Region, 2020 VS 2024 VS 2031
4.5.2 Global PD-1 and PD-L1 Monoclonal Antibody Production by Region, 2020-2025
4.5.3 Global PD-1 and PD-L1 Monoclonal Antibody Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 PD-1 and PD-L1 Monoclonal Antibody Industry Chain
5.2 PD-1 and PD-L1 Monoclonal Antibody Upstream Analysis
5.2.1 PD-1 and PD-L1 Monoclonal Antibody Core Raw Materials
5.2.2 Main Manufacturers of PD-1 and PD-L1 Monoclonal Antibody Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 PD-1 and PD-L1 Monoclonal Antibody Production Mode
5.6 PD-1 and PD-L1 Monoclonal Antibody Procurement Model
5.7 PD-1 and PD-L1 Monoclonal Antibody Industry Sales Model and Sales Channels
5.7.1 PD-1 and PD-L1 Monoclonal Antibody Sales Model
5.7.2 PD-1 and PD-L1 Monoclonal Antibody Typical Distributors

6 Sights by Type
6.1 PD-1 and PD-L1 Monoclonal Antibody Classification by Type
6.1.1 PD-1
6.1.2 PD-L1
6.2 by Type, Global PD-1 and PD-L1 Monoclonal Antibody Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global PD-1 and PD-L1 Monoclonal Antibody Revenue, 2020-2031
6.4 by Type, Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume, 2020-2031
6.5 by Type, Global PD-1 and PD-L1 Monoclonal Antibody Price, 2020-2031

7 Sights by Product Name
7.1 PD-1 and PD-L1 Monoclonal Antibody Classification by Product Name
7.1.1 Pembrolizumab
7.1.2 Nivolumab
7.1.3 Cemiplimab
7.1.4 Toripalimab
7.1.5 Sintilimab
7.1.6 Tislelizumab
7.1.7 Camrelizumab
7.1.8 Penpulimab
7.1.9 Retifanlimab
7.2 by Product Name, Global PD-1 and PD-L1 Monoclonal Antibody Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Product Name, Global PD-1 and PD-L1 Monoclonal Antibody Revenue, 2020-2031
7.4 by Product Name, Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume, 2020-2031
7.5 by Product Name, Global PD-1 and PD-L1 Monoclonal Antibody Price, 2020-2031

8 Sights by Dosage Strength
8.1 PD-1 and PD-L1 Monoclonal Antibody Classification by Dosage Strength
8.1.1 100 mg / Vial
8.1.2 200 mg / Vial
8.1.3 240 mg / Vial
8.1.4 300 mg / Vial
8.2 by Dosage Strength, Global PD-1 and PD-L1 Monoclonal Antibody Market Size & CAGR, 2020 VS 2024 VS 2031
8.3 by Dosage Strength, Global PD-1 and PD-L1 Monoclonal Antibody Revenue, 2020-2031
8.4 by Dosage Strength, Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume, 2020-2031
8.5 by Dosage Strength, Global PD-1 and PD-L1 Monoclonal Antibody Price, 2020-2031

9 Sights by Application
9.1 PD-1 and PD-L1 Monoclonal Antibody Segment by Application
9.1.1 Solid Tumors
9.1.2 Blood-related Tumors
9.2 by Application, Global PD-1 and PD-L1 Monoclonal Antibody Market Size & CAGR, 2020 VS 2024 VS 2031
9.3 by Application, Global PD-1 and PD-L1 Monoclonal Antibody Revenue, 2020-2031
9.4 by Application, Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume, 2020-2031
9.5 by Application, Global PD-1 and PD-L1 Monoclonal Antibody Price, 2020-2031

10 Sales Sights by Region
10.1 By Region, Global PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020 VS 2024 VS 2031
10.2 By Region, Global PD-1 and PD-L1 Monoclonal Antibody Revenue, 2020-2031
10.3 By Region, Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume, 2020-2031
10.4 North America
10.4.1 North America PD-1 and PD-L1 Monoclonal Antibody Market Size & Forecasts, 2020-2031
10.4.2 By Country, North America PD-1 and PD-L1 Monoclonal Antibody Market Size Market Share
10.5 Europe
10.5.1 Europe PD-1 and PD-L1 Monoclonal Antibody Market Size & Forecasts, 2020-2031
10.5.2 By Country, Europe PD-1 and PD-L1 Monoclonal Antibody Market Size Market Share
10.6 Asia Pacific
10.6.1 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Market Size & Forecasts, 2020-2031
10.6.2 By Country/Region, Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Market Size Market Share
10.7 South America
10.7.1 South AmericaPD-1 and PD-L1 Monoclonal Antibody Market Size & Forecasts, 2020-2031
10.7.2 By Country, South America PD-1 and PD-L1 Monoclonal Antibody Market Size Market Share
10.8 Middle East & Africa

11 Sales Sights by Country Level
11.1 By Country, Global PD-1 and PD-L1 Monoclonal Antibody Market Size & CAGR，2020 VS 2024 VS 2031
11.2 By Country, Global PD-1 and PD-L1 Monoclonal Antibody Revenue, 2020-2031
11.3 By Country, Global PD-1 and PD-L1 Monoclonal Antibody Sales Volume, 2020-2031
11.4 United States
11.4.1 United States PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.4.2 By Company, United States PD-1 and PD-L1 Monoclonal Antibody Sales Volume Market Share, 2024
11.4.3 by Type, United States PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.4.4 by Application, United States PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.5 Europe
11.5.1 Europe PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.5.2 By Company, Europe PD-1 and PD-L1 Monoclonal Antibody Sales Volume Market Share, 2024
11.5.3 by Type, Europe PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.5.4 by Application, Europe PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.6 China
11.6.1 China PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.6.2 By Company, China PD-1 and PD-L1 Monoclonal Antibody Sales Volume Market Share, 2024
11.6.3 by Type, China PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.6.4 by Application, China PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.7 Japan
11.7.1 Japan PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.7.2 By Company, Japan PD-1 and PD-L1 Monoclonal Antibody Market Share, 2024
11.7.3 by Type, Japan PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.7.4 by Application, Japan PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.8 South Korea
11.8.1 South Korea PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.8.2 By Company, South Korea PD-1 and PD-L1 Monoclonal Antibody Market Share, 2024
11.8.3 by Type, South Korea PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.8.4 by Application, South Korea PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.9 Southeast Asia
11.9.1 Southeast Asia PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.9.2 By Company, Southeast Asia PD-1 and PD-L1 Monoclonal Antibody Market Share, 2024
11.9.3 by Type, Southeast Asia PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.9.4 by Application, Southeast Asia PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.10 India
11.10.1 India PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.10.2 By Company, India PD-1 and PD-L1 Monoclonal Antibody Market Share, 2024
11.10.3 by Type, India PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.10.4 by Application, India PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.11 Middle East & Africa
11.11.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Market Size, 2020-2031
11.11.2 By Company, Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Market Share, 2024
11.11.3 by Type, Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031
11.11.4 by Application, Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Market Size, Share, 2024 VS 2031

12 Manufacturers Profile
12.1 Merk
12.1.1 Merk Company Information, Head Office, Market Area, and Industry Position
12.1.2 Merk PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.1.3 Merk PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.1.4 Merk Company Profile and Main Business
12.1.5 Merk Recent Developments
12.2 Bristol-Myers Squibb Company
12.2.1 Bristol-Myers Squibb Company Company Information, Head Office, Market Area, and Industry Position
12.2.2 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.2.3 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.2.4 Bristol-Myers Squibb Company Company Profile and Main Business
12.2.5 Bristol-Myers Squibb Company Recent Developments
12.3 Roche
12.3.1 Roche Company Information, Head Office, Market Area, and Industry Position
12.3.2 Roche PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.3.3 Roche PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.3.4 Roche Company Profile and Main Business
12.3.5 Roche Recent Developments
12.4 Pfizer
12.4.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
12.4.2 Pfizer PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.4.4 Pfizer Company Profile and Main Business
12.4.5 Pfizer Recent Developments
12.5 AstraZeneca
12.5.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
12.5.2 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.5.3 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.5.4 AstraZeneca Company Profile and Main Business
12.5.5 AstraZeneca Recent Developments
12.6 Junshi Biosciences
12.6.1 Junshi Biosciences Company Information, Head Office, Market Area, and Industry Position
12.6.2 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.6.3 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.6.4 Junshi Biosciences Company Profile and Main Business
12.6.5 Junshi Biosciences Recent Developments
12.7 Innovent
12.7.1 Innovent Company Information, Head Office, Market Area, and Industry Position
12.7.2 Innovent PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.7.3 Innovent PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.7.4 Innovent Company Profile and Main Business
12.7.5 Innovent Recent Developments
12.8 Hengrui
12.8.1 Hengrui Company Information, Head Office, Market Area, and Industry Position
12.8.2 Hengrui PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.8.3 Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.8.4 Hengrui Company Profile and Main Business
12.8.5 Hengrui Recent Developments
12.9 BeiGene
12.9.1 BeiGene Company Information, Head Office, Market Area, and Industry Position
12.9.2 BeiGene PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.9.3 BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.9.4 BeiGene Company Profile and Main Business
12.9.5 BeiGene Recent Developments
12.10 Alphamab Oncology
12.10.1 Alphamab Oncology Company Information, Head Office, Market Area, and Industry Position
12.10.2 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.10.3 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.10.4 Alphamab Oncology Company Profile and Main Business
12.10.5 Alphamab Oncology Recent Developments
12.11 Cstone
12.11.1 Cstone Company Information, Head Office, Market Area, and Industry Position
12.11.2 Cstone PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.11.3 Cstone PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.11.4 Cstone Company Profile and Main Business
12.11.5 Cstone Recent Developments
12.12 Akeso
12.12.1 Akeso Company Information, Head Office, Market Area, and Industry Position
12.12.2 Akeso PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.12.3 Akeso PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.12.4 Akeso Company Profile and Main Business
12.12.5 Akeso Recent Developments
12.13 Henlius Biotech
12.13.1 Henlius Biotech Company Information, Head Office, Market Area, and Industry Position
12.13.2 Henlius Biotech PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.13.3 Henlius Biotech PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.13.4 Henlius Biotech Company Profile and Main Business
12.13.5 Henlius Biotech Recent Developments
12.14 Lepu Biopharma
12.14.1 Lepu Biopharma Company Information, Head Office, Market Area, and Industry Position
12.14.2 Lepu Biopharma PD-1 and PD-L1 Monoclonal Antibody Models, Specifications, and Application
12.14.3 Lepu Biopharma PD-1 and PD-L1 Monoclonal Antibody Sales Volume, Revenue, Price and Gross Margin, 2020-2025
12.14.4 Lepu Biopharma Company Profile and Main Business
12.14.5 Lepu Biopharma Recent Developments

13 Conclusion

14 Appendix
14.1 Research Methodology
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Market Estimation Model
14.4 Disclaimer

According to YH Research, the global market for PD-1 and PD-L1 Monoclonal Antibody should grow from US$ 56337 million in 2024 to US$ 112638 million by 2031, with a CAGR of 10.5% for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

PD-1 and PD-L1 Monoclonal Antibody

According to YH Research, the global market for PD-1 and PD-L1 Monoclonal Antibody should grow from US$ 56337 million in 2024 to US$ 112638 million by 2031, with a CAGR of 10.5% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

PD-1 and PD-L1 monoclonal antibodies are therapeutic antibodies designed to restore T-cell–mediated antitumor immunity by blocking the immune checkpoint pathway exploited by tumors, addressing the limitations of conventional chemotherapy and targeted therapies in advanced solid tumors, including insufficient response durability, high toxicity, and acquired resistance. Originating from discoveries in the 1990s that identified PD-1 and PD-L1 as key regulators of tumor-induced immune suppression, researchers engineered monoclonal antibodies capable of disrupting this pathway, leading to the approval of the first agents in 2014 and reshaping the global oncology landscape. Their development and manufacturing rely on a sophisticated upstream biopharmaceutical ecosystem encompassing nucleic acid materials for cell line engineering, expression vectors, mammalian cell culture media, bioreactors, chromatography resins, filtration consumables, aseptic filling components, and analytical instruments, all of which ensure structural integrity, batch consistency, and clinical reliability of the final antibody products.In 2024, global sales of PD-1 and PD-L1 monoclonal antibodies reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.

From a market standpoint, PD-1 and PD-L1 monoclonal antibodies have evolved from a landscape dominated by a few originator products to one characterized by broad participation, rapid indication expansion, and growing adoption across diverse clinical settings. Clinical guidelines worldwide increasingly position these therapies as standard options in major tumor types, with use extending from late-stage treatment into adjuvant and neoadjuvant settings. The emergence of biosimilars and expanding access in emerging markets further reshape the competitive environment, creating a multi-tiered market where originator drugs, improved formulations, and domestically developed innovations coexist.

Looking ahead, differentiation and combination strategies will define the next stage of development. Companies are pursuing engineered antibodies with enhanced affinity, reduced immunogenicity, and more convenient administration profiles, while combination regimens with immunomodulators, targeted agents, cell therapies, radiotherapy, or chemotherapy aim to expand responder populations and delay resistance. Advances in companion diagnostics, biomarker stratification, and functional imaging will enhance precision in patient selection, driving the market toward more tailored, combination-based, and long-term treatment paradigms.

Key growth drivers include persistent unmet clinical needs, strong demand in high-mortality cancers, supportive regulatory frameworks for innovative immunotherapies, sustained investment in biopharmaceutical R&D, and increasing clinical experience at treatment centers. In parallel, maturing supply chains, rising localization of critical raw materials, and expanded manufacturing capacity provide structural support for continued market expansion. Ecosystem players such as CROs, CDMOs, and diagnostic developers further accelerate innovation by reducing development barriers and enabling faster iteration.

However, the field faces notable constraints. Response rates remain suboptimal in several tumor types, and resistance mechanisms—both intrinsic and acquired—limit therapeutic durability. High treatment costs and variability in reimbursement policies contribute to uneven access, particularly in developing regions, while intensifying market competition exerts pricing pressure and compresses margins. Moreover, the inherent technical complexity of biologics manufacturing and the stringent requirements for batch consistency pose challenges for new entrants. The pace of future growth will depend on scientific breakthroughs, payer policy evolution, and the accumulation of real-world evidence that validates long-term clinical value.

This report aims to provide a comprehensive study of the global market for PD-1 and PD-L1 Monoclonal Antibody. 
Report Highlights:
(1) Global PD-1 and PD-L1 Monoclonal Antibody market size (sales volume & revenue), history data from 2020-2025, and forecast data from 2026 to 2031.

(2) Global PD-1 and PD-L1 Monoclonal Antibody market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(3) China PD-1 and PD-L1 Monoclonal Antibody market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(4) Global PD-1 and PD-L1 Monoclonal Antibody segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global PD-1 and PD-L1 Monoclonal Antibody segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Global major production regions of PD-1 and PD-L1 Monoclonal Antibody, capacity, production and trends.

(7) PD-1 and PD-L1 Monoclonal Antibody industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
    PD-1
    PD-L1

Market segment by Product Name, covers
    Pembrolizumab
    Nivolumab
    Cemiplimab
    Toripalimab
    Sintilimab
    Tislelizumab
    Camrelizumab
    Penpulimab
    Retifanlimab
    Others

Market segment by Dosage Strength, covers
    100 mg / Vial
    200 mg / Vial
    240 mg / Vial
    300 mg / Vial

Market segment by Application, can be divided into
    Solid Tumors
    Blood-related Tumors

Market segment by players, this report covers
    Merk
    Bristol-Myers Squibb Company
    Roche
    Pfizer
    AstraZeneca
    Junshi Biosciences
    Innovent
    Hengrui
    BeiGene
    Alphamab Oncology
    Cstone
    Akeso
    Henlius Biotech
    Lepu Biopharma